Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-06-11 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于股东减持股份计划数量过半的进展公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the progress of a shareholder's plan to reduce their shareholding in the company. It details the number of shares reduced, the dates, prices, and the impact on total shareholding percentages. It references compliance with securities laws and stock exchange rules, and includes tables summarizing share reduction transactions. There is no financial statement, earnings data, or management discussion of financial results. The document is a regulatory announcement about shareholding changes by significant shareholders, specifically about the progress of a share reduction plan. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2020-06-11 Chinese
关于2020年累计新增借款超过上年末净资产百分之二十的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shenzhen BGI Genomics Co., Ltd. regarding the cumulative new borrowings in 2020 exceeding 20% of the net assets at the end of the previous year. It includes specific financial data about borrowings, their classification, and an analysis of the impact on debt repayment ability. The document references regulatory rules related to bond issuance and disclosure requirements. The length is 1483 characters, which is relatively short and the document is clearly an announcement of a financing event (new borrowings) rather than a full financial report or audit. It does not contain comprehensive financial statements or detailed management discussion but focuses on capital/financing update information. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-06-08 Chinese
关于全资子公司申报医疗器械注册获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acceptance of a medical device registration application for a product by a wholly-owned subsidiary. It includes details about the product, regulatory approval status, and potential impact on the company. The text is relatively short (1839 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is an announcement of a regulatory event related to product registration, not a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-06-05 Chinese
关于股份回购实施结果暨股份变动公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement about the completion of a share repurchase program by Shenzhen BGI Genomics Co., Ltd. It includes specifics on the number of shares repurchased, prices, compliance with regulations, and the intended use of the repurchased shares for an employee stock ownership plan. The document also references previous announcements and reports related to the repurchase but itself provides the final results and details of the share buyback. The length is about 4304 characters, which is sufficient for a detailed announcement but not a full financial report. The content focuses on the share repurchase implementation results and related shareholding changes, which aligns with the category of Transaction in Own Shares (POS). It is not a simple announcement of a report publication, nor is it a full annual or interim report, nor a regulatory filing or other categories. Therefore, the correct classification is POS with high confidence.
2020-06-03 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase plan. It details the number of shares repurchased, prices, compliance with regulations, and the timeline of the repurchase activities. It references previous announcements and reports related to the share buyback but does not contain full financial statements or detailed financial analysis. The document length is short (1892 characters) and focuses on the update of the share repurchase progress rather than a full report or initial announcement of financial results. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares.
2020-06-03 Chinese
关于首次回购公司股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding the company's first share repurchase. It details the number of shares repurchased, the price range, total amount spent, and compliance with relevant regulations. The document references the company's board and shareholder meeting approvals for the repurchase plan and provides specifics about the timing and volume of the repurchase. There is no financial statement or comprehensive report content, but rather a disclosure of a share buyback event. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company buying back its own shares.
2020-05-27 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.